Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Innovent Biologics Inc (1801.HK)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date	Stock Price (HK$)	Price Target (HK$)	Rating
2022-02-28	34.95	60.00	Buy
2022-04-06	29.55	43.00	Buy
2022-06-14	26.50	39.30	Buy
2022-08-05	35.80	42.00	Buy
2023-03-01	40.55	52.10	Buy
2023-04-28	37.45	48.10	Buy
2023-08-24	34.65	51.20	Buy
2023-10-30	47.05	55.80	Buy
2024-03-21	38.10	57.70	Buy
2024-05-09	40.55	57.40	Buy
2024-08-29	43.50	60.70	Buy
2024-11-19	35.90	61.40	Buy
2025-03-26	39.05	59.00	Buy
2025-04-11	47.75	66.30	Buy
2025-05-23	58.60	75.40	Buy

Disclosures

UBS holds a long or short position of 0.5% or more of the listed shares of this company.

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.